Please assess the completion status of the following clinical trial:

Trial Title: Rebif New Formulation (RNF) Quality of Life (QOL) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject with a relapsing form of MS; diagnosis of MS is in accordance with the McDonald criteria~2. Subject currently taking Rebif 44mcg tiw, and has been on this treatment for at least 6 months (24 weeks) prior to study enrollment~3. Subject currently using Rebiject II and 29 gauge needle~4. Subject is between 18 and 60 years old inclusive~5. Subject is able to read and understand English~6. Subject is willing to follow study procedures~7. Subject has given written informed consent and signed HIPAA~8. Female subjects must not be either pregnant or breast-feeding and must lack childbearing potential, as defined by either: i) Being post-menopausal or surgically sterile, or ii) Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study. (Confirmation required within 30 days prior to start of the study)~Exclusion Criteria:~1. Use of any other injectable medications on a regular basis during the week prior to the screening period or during the screening or treatment periods. Receiving a single injection for treatment or prophylaxis of a condition unrelated to the subject's multiple sclerosis or the subject's Rebif® therapy (e.g., receiving a influenza or pneumococcus vaccination) is acceptable~2. Subject receiving MS therapy in addition (i.e., combination therapy) to Rebif® within 3 months prior to study enrollment or at any time during study protocol.~3. Subjects who have previously been on Rebif New Formulation (RNF).~4. Subject with progressive forms of Multiple Sclerosis (MS).~5. Subject with history of any chronic pain syndrome.~6. Subject has any other disease apart from MS that could better explain the subjects signs and symptoms.~7. Subject has complete transverse myelitis or bilateral optic neuritis.~8. Subjects that use any investigational drug or experimental procedure within 12 weeks of visit 1.~9. Subject received oral or systemic corticosteroids or ACTH within 30 days of visit 1 (prior to enrollment).~10. Subject has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase \> 2.5 times the upper limit of the normal values.~11. Subject has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal.~12. Subject suffers from other current autoimmune disease.~13. Subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol~14. Subject is pregnant or attempting to conceive~15. Visual or physical impairment that precludes completion of diaries and questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Rebif New Formulation - Non Titrated
- 2 (Type: ACTIVE_COMPARATOR): Rebif New Formulation - Titrated

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete